We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury

By LabMedica International staff writers
Posted on 08 Jan 2025

Drug-induced kidney injury, also known as nephrotoxicity, is a frequent complication in clinical medicine, occurring when drugs damage the kidneys. More...

This can result from various medications, including anti-inflammatory, antibacterial, antiretroviral, and chemotherapeutic drugs, and may lead to the discontinuation or restriction of treatment. Current biomarkers are often too slow to detect early signs of kidney damage. Researchers have now identified six new biomarkers that could enable quicker and more sensitive detection of kidney injury, paving the way for safer drug development and better patient outcomes. Early detection of kidney damage could allow clinicians to intervene sooner, potentially reducing long-term harm and improving patient health in diverse medical settings.

These newly discovered biomarkers, identified by researchers at Boston Medical Center (Boston, MA, USA), may offer a more sensitive approach compared to current standards for monitoring kidney health, leading to more tolerable treatment options. The research team analyzed urinary protein biomarkers in both healthy volunteers and patients being treated for mesothelioma with a chemotherapy drug known to be toxic to the kidneys. The six biomarkers they identified are primarily produced by the kidneys in response to injury or inflammation, enabling faster detection of kidney injury than traditional blood tests like serum creatinine, which can take days to show abnormal levels. The research team now aims to explore whether these biomarkers can be applied more broadly for monitoring kidney health in clinical trials.

"These biomarkers, which can be measured in the urine, could help clinicians detect kidney damage within 24 hours of injury, enabling more timely monitoring during drug development and better treatment of patients who are at risk in clinical settings," said Sushrut Waikar, MD, MPH, first author on the paper published in Clinical Pharmacology & Therapeutics. "These biomarkers have the potential to make a real difference in how we monitor kidney health and manage patients at risk for kidney damage. We are hopeful that these findings will contribute to better strategies for preserving kidney function and improving patient care, as well as advancing safer drug development."


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.